In order to shorten the time for regulatory review of a new drug application (NDA) or biologic license application(BLA), more and more biotech and pharmaceutical companies prepare their Bioresearch Monitoring (BIMO) program packages as part of their initial submissions. In this paper, we walk the reader through a process of producing BIMO information, particularly the subject-level data line listings by clinical site (by-site listings) and the summary-level clinical site (CLINSITE) dataset. This paper concludes with methods of preparing electronic Common Technical Document (eCTD) documentation, such as data definition (define.xml) and reviewer’s guide, to support the CLINSITE dataset. In addition, we discuss challenges as we share our experience in planning, producing, and quality control (QC) for a successful BIMO package.
DownloadDate: Tuesday, May 19th, 2020
Presented at: PharmaSUG 2020